Abstract: Provided are methods and uses for treating a cancer or a tumor. In some aspects, the provided methods and uses involve contacting a sample, e.g., containing tumor cells, with a phthalocyanine dye conjugated to a targeting molecule that binds a protein on tumor cell, and illuminating the sample with a wavelength of light suitable for the activation of the phthalocyanine dye. In some aspects, the methods and uses also involve administering the illuminated sample to a subject, such as a subject having a cancer or a tumor. The methods and uses described herein provide for stimulation of the anti-cancer immune response in the subject and the reduction of growth and/or elimination of cancers, tumors and tumor cells in the subject. Also provided are compositions and combinations for use in the provided methods.

Abstract: Provided are compositions, combinations, and methods and uses for treating a subject having a tumor, lesion or cancer. In some aspects, the methods and uses include administering a targeting molecule that binds PD-L1, conjugated with phthalocyanine dye, such as IR700. In some aspects, after administration of the conjugate, a target area is illuminated with a wavelength of light suitable for the activation of the conjugate. In some aspects, the illumination leads to the killing of PD-L1-expressing cells. The provided embodiments result in growth inhibition, volume reduction, and elimination of tumors, lesions or cancers, including metastatic tumor cells, invasive tumor cells, heterogeneous tumors and/or tumors that are not responsive to and/or resistant to other therapies.

Abstract: The present disclosure relates to near-infrared (NIR) photoimmunotherapy (PIT) for treating a subject having a cancer, such as a cancer comprising a first tumor or a primary tumor, metastatic tumor cells and/or invasive tumor cells. The method includes administering to the subject a targeting molecule that binds CD25 conjugated with phthalocyanine dye, such as IR700, and administering an immune checkpoint inhibitor such as an anti PD-1 antibody, followed by illuminating the first tumor or primary tumor with a wavelength of light suitable for the activation of the phthalocyanine dye.

Abstract: Provided are compositions, combinations, and methods and uses for treating a subject having a tumor or lesion, including those not responsive or resistant to prior therapeutic treatments, such as prior immune checkpoint inhibitor treatments. In some aspects, the methods include administering to the subject a targeting molecule that binds CTLA-4 conjugated with phthalocyanine dye, such as IR700. In some cases, the methods include administering an immune modulatory agent. The tumor or lesion, in some cases, a first tumor, is illuminated with a wavelength of light suitable for the activation of the phthalocyanine dye of the conjugate. The provided methods and uses provide for growth inhibition, volume reduction, and elimination of tumors and tumor cells including primary tumors, metastatic tumor cells, and/or invasive tumor cells. Also provided are compositions, combinations, methods and uses for provoking or enhancing systemic and local immune responses and for synergistic responses against tumor growth.

Abstract: Provided are methods involving the use of biomarkers, in relation to photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on tumor cell, for example, an IR700-antibody conjugate, and combination therapies, for example, that include photoimmunotherapy and an additional therapeutic agent, such as an immune modulating agent. In some aspects, the provided embodiments can be used to identify or select subjects for photoimmunotherapy and/or the combination therapy, or to assess the likelihood of response to photoimmunotherapy and/or to the additional therapeutic agents. Features of the methods and uses provide various advantages, such as improved efficacy. In some aspects, the provided embodiments can be used to provide personalized medicine and tailored therapy regimens for subjects.

Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.

Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.

Abstract: Provided are methods for manufacturing a conjugate containing a phthalocyanine dye, including methods that include one or more steps of preparing or producing the conjugate, formulating the conjugate and packaging the conjugate. In some aspects, the manufacturing methods result in the generation of a stable conjugate. Also provided are stable phthalocyanine dye conjugates, compositions and articles of manufacture containing the stable conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.

Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.

Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.

Abstract: Provided are methods for manufacturing a conjugate containing a phthalocyanine dye, including methods that include one or more steps of preparing or producing the conjugate, formulating the conjugate and packaging the conjugate. In some aspects, the manufacturing methods result in the generation of a stable conjugate. Also provided are stable phthalocyanine dye conjugates, compositions and articles of manufacture containing the stable conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.

Abstract: Disclosed herein, inter alia, are compositions and methods for modulating the activity of N-acylethanolamine acid amidase for the treatment of a pathological state, including pain, an inflammatory condition, or a neurodegenerative disorder.

Abstract: Provided are conjugates, e.g., dual conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye in the dual conjugate. In some embodiments, the dual conjugate contains a targeting molecule and a therapeutic agent. In some embodiments, the phthalocyanine-dye in the conjugate, e.g., dual conjugate, can be activated by irradiation with near-infrared light. Also provided are therapeutic methods using the conjugates, e.g., dual conjugates, and compositions for treatment of a lesion associated with diseases and conditions, including tumors or cancers. Features of the conjugates, e.g., dual conjugates, compositions, combinations and methods, including the dose of the conjugate, provide various advantages, such as efficient delivery and targeting of the therapeutic agent to the site of the lesion.

Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.

Abstract: Provided are methods for manufacturing a conjugate containing a phthalocyanine dye, including methods that include one or more steps of preparing or producing the conjugate, formulating the conjugate and packaging the conjugate. In some aspects, the manufacturing methods result in the generation of a stable conjugate. Also provided are stable phthalocyanine dye conjugates, compositions and articles of manufacture containing the stable conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.

Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.

Abstract: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

Abstract: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

Abstract: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

Abstract: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.